TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16818564

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (3 microg/kg per day) and folate (100 microg/kg per day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lower dose of folate (60 microg/kg per day)
Number of subjects: 64
Study: 15361820

Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism (HyperT)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (HypoT)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Normal subjects (EuT)
Number of subjects: 347
Study: 10945496

Group type: EXPERIMENTAL
Intervention: Screening arm (mammographic screening)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Operable invasive cases
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Nottingham Prognostic Index (NPI)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Pathological size and histological type
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Pathology indicators of survival in NPI
Number of subjects: 1029
Study: 9390112

Group type: EXPERIMENTAL
Intervention: Montelukast 50 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Montelukast 2 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Montelukast 0.4 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8238707

Group type: EXPERIMENTAL
Intervention: Arthroscopic group (fully arthroscopic reconstruction)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Open group (limited open reconstruction)
Number of subjects: 2
Study: 2862946

Group type: EXPERIMENTAL
Intervention: Temazepam (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31285834

Group type: EXPERIMENTAL
Intervention: Mindfulness-based program 'Early Minds' delivered at least three times a week for 8 weeks; educators trained and supported via an app.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mindfulness-based program 'Early Minds'
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 6
Study: 28651448

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 362
Study: 27127136

Group type: EXPERIMENTAL
Intervention: Acetium lozenge (slow-release L-Cysteine)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 25029426

Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Aldosterone infusion (0.7 μg/kg/h for 12.5 h)
Number of subjects: 29
Study: 22685046

Group type: EXPERIMENTAL
Intervention: 12-week school-based healthy lifestyle programme (Sport for LIFE)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 416
Study: 18363032

Group type: EXPERIMENTAL
Intervention: Monascus purpureus Went rice (600 mg twice per day for one month, then once daily)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no antidyslipidemic therapy)
Number of subjects: 72
Study: 15601270

Group type: EXPERIMENTAL
Intervention: Dobutamine (n = 12)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Phenylephrine (n = 12)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (n = 13)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intravenous colloid (n = 18)
Number of subjects: 99
Study: 12381337

Group type: EXPERIMENTAL
Intervention: Orlistat given as a capsule with the meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orlistat mixed into the test meal before ingestion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Test meal without Orlistat
Number of subjects: 12
Study: 11247198

Group type: EXPERIMENTAL
Intervention: Folic acid containing multivitamin preparation (4 mg of folic acid, calcium, iron, zinc, vitamins A, B1, B2, B6, C, D, and nicotinamide)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo (calcium and iron only)
Number of subjects: 466
Study: 9105061

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (SLM) 50 microg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination of FP and SLM
Number of subjects: 46
Study: 8456421

Group type: EXPERIMENTAL
Intervention: sulotroban (2 mg/min, 4 mg/min, 8 mg/min)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: sulotroban
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 3104991

Group type: EXPERIMENTAL
Intervention: Enprostil (70 micrograms oral dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enprostil (10 micrograms/ml) in rats
Number of subjects: 10
Study: 31387629

Group type: EXPERIMENTAL
Intervention: Upper-body yoga training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Abdominal breathing program
Number of subjects: 84
Study: 28862373

Group type: EXPERIMENTAL
Intervention: Thalassemic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 0
Study: 26369884

Group type: EXPERIMENTAL
Intervention: Telephone-delivered mutual peer support intervention
Number of subjects: 443

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 443
Study: 23781982

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS ipsilateral to the symptomatic ear (n=21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS contralateral to the symptomatic ear (n=19)
Number of subjects: 40
Study: 22471135

Group type: EXPERIMENTAL
Intervention: Medicated threads moxibustion of Zhuang nationality
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ergotamine and Caffeine tablets (oral administration)
Number of subjects: 120
Study: 20937992

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m² on day 1 and topotecan 0.75 mg/m² on days 1-5 followed by paclitaxel 175 mg/m² on day 1 and carboplatin (AUC = 5) on day 1 for four cycles, then four cycles of paclitaxel and carboplatin.
Number of subjects: 819

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel for eight cycles.
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Cisplatin and topotecan followed by carboplatin and paclitaxel.
Number of subjects: 819

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel.
Number of subjects: 819
Study: 18260172

Group type: EXPERIMENTAL
Intervention: IV ibandronate (2 mg every 2 months)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: IV ibandronate (3 mg every 3 months)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Daily oral ibandronate (2.5 mg)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: IV ibandronate
Number of subjects: 1395
Study: 16308255

Group type: EXPERIMENTAL
Intervention: Mepivacaine applied in the epipharyngeal space
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Mepivacaine and Control (placebo)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 98
Study: 12798874

Group type: EXPERIMENTAL
Intervention: Chemical removal of zona pellucida by using acidic Tyrode's solution
Number of subjects: 257

Group type: COMPARATOR
Intervention: No removal (controls)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Chemical removal of zona pellucida in embryos with delayed development
Number of subjects: 257

Group type: COMPARATOR
Intervention: No removal (controls) in embryos with delayed development
Number of subjects: 257
Study: 10653210

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg sustained-release twice daily + 5 mg immediate-release with morning dose)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methylphenidate (15, 30, and 60 mg immediate-release in ascending doses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8704113

Group type: EXPERIMENTAL
Intervention: Biostat 1000 dialysate monitoring device
Number of subjects: 29

Group type: COMPARATOR
Intervention: Blood-side measurements
Number of subjects: 29
Study: 30417842

Group type: COMPARATOR
Intervention: Fluoride varnish (Group 2)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Resin infiltrate (Group 1)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Resin infiltrate (Group 3)
Number of subjects: 132
Study: 26771281

Group type: EXPERIMENTAL
Intervention: Current Nutrition Facts table (NFt)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Modified Nutrition Facts tables (NFt)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unequal serving sizes on NFts
Number of subjects: 26
Study: 23916901

Group type: EXPERIMENTAL
Intervention: Primary suturing (Group 1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Non-suturing (Group 2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168
Study: 23011728

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (150 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prandial insulin
Number of subjects: 10
Study: 17660722

Group type: EXPERIMENTAL
Intervention: Taiji-Qigong (TQ) training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-list control (WC) group
Number of subjects: 49
Study: 15639293

Group type: EXPERIMENTAL
Intervention: Combination therapy (100 microg/week pegylated interferon alfa-2b and 100 mg/day lamivudine)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Monotherapy (100 microg/week pegylated interferon alfa-2b and placebo)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 307

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combination therapy and monotherapy
Number of subjects: 307
Study: 12189483

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal prosthetic repair (TEPP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open Stoppa procedure
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 10437870

Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 0
Study: 7776170

Group type: EXPERIMENTAL
Intervention: Ultrasonic curets (U)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Manual curets (M)
Number of subjects: 19
Study: 2140160

Group type: EXPERIMENTAL
Intervention: Digitalis derivatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study: 468749

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison boys
Number of subjects: 0
Study: 31849035

Group type: EXPERIMENTAL
Intervention: 10 mg of oral hyoscine twice daily for 1 week, followed by once daily for 1 week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine expectant management
Number of subjects: 100
Study: 28912358

Group type: EXPERIMENTAL
Intervention: COC plus spironolactone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 46
Study: 25583916

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral counseling (7 sessions from antenatal to 6 months postpartum)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Routine counseling (equal number of sessions as intervention)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral counseling
Number of subjects: 452
Study: 24881286

Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 350

Group type: COMPARATOR
Intervention: Crotamiton 10% cream
Number of subjects: 350
Study: 21275446

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil + amlodipine + HCTZ
Number of subjects: 0
Study: 19025972

Group type: EXPERIMENTAL
Intervention: Oral topotecan at a dose of 1.2 mg/m2 twice daily for 5 days (Arm A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral topotecan once daily for 10 days (Arm B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nonhematologic toxicity
Number of subjects: 90
Study: 16406239

Group type: EXPERIMENTAL
Intervention: Mitochondrial A1555G mutation screening in families with NSHL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Screening of nuclear genes (GJB2, GJB3, GJB6)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exploration of mitochondrial 12S rRNA gene
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exploration of tRNASer(UCN) gene
Number of subjects: 100
Study: 15196585

Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (0.25, 0.5, 1, 2.5, 5, or 10 mg) administered via 10 min i.v. infusion
Number of subjects: 94
Study: 11513288

Group type: EXPERIMENTAL
Intervention: Specialized education program for paramedics
Number of subjects: 0
Study: 9018183

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 micrograms/dose) with the first and third dose of albuterol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline placebo instead of ipratropium
Number of subjects: 90
Study: 8359791

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study: 3488361

Group type: EXPERIMENTAL
Intervention: Microamperage electrical stimulation of trigger points with the Electro-Acuscope 80
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study: 29419875

Group type: COMPARATOR
Intervention: KIR2DL4*011 allele in ALL group
Number of subjects: 590

Group type: COMPARATOR
Intervention: 10A type KIR2DL4 allele in ALL group
Number of subjects: 590

Group type: COMPARATOR
Intervention: KIR2DL4 alleles in AML and CML groups
Number of subjects: 590
Study: 27512827

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched spread
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (margarine spread without phytosterols)
Number of subjects: 100
Study: 25634521

Group type: EXPERIMENTAL
Intervention: Natural citric acid (harmless substance)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Potentially harmful substance (agro-chemical acid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Citric acid at C3 dose
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 39
Study: 22990631

Group type: EXPERIMENTAL
Intervention: Gastric lavage with 10 ml/kg of normal saline
Number of subjects: 244

Group type: COMPARATOR
Intervention: No gastric lavage (control group)
Number of subjects: 244
Study: 20093904

Group type: EXPERIMENTAL
Intervention: SISTEr study
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: TOMUS study
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Prior surgery for pelvic organ prolapse and SUI
Number of subjects: 1252
Study: 18713273

Group type: EXPERIMENTAL
Intervention: MALP-2 (0.125-1 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 12
Study: 15829043

Group type: EXPERIMENTAL
Intervention: Tele-ECG recorded by the patient and transmitted to a cardiology call centre
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Tele-ECG
Number of subjects: 158
Study: 11940070

Group type: EXPERIMENTAL
Intervention: Rofecoxib (cumulative dose of 25 mg administered in doses of 6.25 mg, 6.25 mg, and 12.5 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 10080652

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol (Painlax and Tramal)
Number of subjects: 0
Study: 7583525

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) replacement therapy for 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 12
Study: 2076716

Group type: EXPERIMENTAL
Intervention: Liposomal preparation of beta‐methasone dipropionate (0.039%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial propylene glycol-gel containing 0.064% beta‐methasone dipropionate
Number of subjects: 20
Study: 7042366

Group type: EXPERIMENTAL
Intervention: Indoprofen (200 mg q.i.d.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg q.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31463614

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Trans-diagnostic risk factors (financial stress, education level, exposure to traumatic events)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Lower education levels
Number of subjects: 977
Study: 30835202

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) derived from GWAS (p<5×10‐05)
Number of subjects: 334398

Group type: EXPERIMENTAL
Intervention: Multiple risk factors
Number of subjects: 334398
Study: 31887169

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin spray (800 μg, 2 puffs)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 1107
Study: 28629180

Group type: EXPERIMENTAL
Intervention: Sausages enriched with approximately 250 mg EPA and DHA per 80 g daily for 8 weeks (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Matching placebo sausages (n = 22)
Number of subjects: 44
Study: 24549261

Group type: EXPERIMENTAL
Intervention: Cyclops group (15 knees with cyclops lesions)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No-cyclops group (40 knees without cyclops lesions)
Number of subjects: 55
Study: 23455593

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) at HT7
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 25
Study: 20728875

Group type: EXPERIMENTAL
Intervention: 150 mg twice daily DMXB-A
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75 mg twice daily DMXB-A
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19102866

Group type: EXPERIMENTAL
Intervention: Harmonic imaging ultrasonic integrated backscatter (IBS) in A group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Harmonic imaging ultrasonic integrated backscatter (IBS) in B group
Number of subjects: 72
Study: 16840741

Group type: EXPERIMENTAL
Intervention: Computer-driven weaning
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (physician-controlled weaning)
Number of subjects: 144
Study: 12626975

Group type: EXPERIMENTAL
Intervention: Low-dose LY315920Na/S-5920 (target plasma concentration of 200 ng/mL, n = 196)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: High-dose LY315920Na/S-5920 (target plasma concentration of 800 ng/mL, n = 194)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo (n = 196)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Low-dose LY315920Na/S-5920 (n = 51)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: High-dose LY315920Na/S-5920 (n = 48)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo (n = 46)
Number of subjects: 586
Study: 11735710

Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene cream
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.05% tazarotene cream
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.025% tazarotene cream
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.01% tazarotene cream
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin emollient cream
Number of subjects: 349

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 349
Study: 9709266

Group type: EXPERIMENTAL
Intervention: Screening mammograms for women aged 40-49
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening mammograms for women aged 50 and above
Number of subjects: 0
Study: 8286827

Group type: EXPERIMENTAL
Intervention: Natural interferon (IFN)‐alpha
Number of subjects: 22
Study: 2823593

Group type: EXPERIMENTAL
Intervention: Red kidney beans breakfast meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bran cereal breakfast meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: White bread breakfast meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standard whole-wheat-bread meal (4 hours later)
Number of subjects: 6
Study: 29849105

Group type: EXPERIMENTAL
Intervention: LOW-INR group (target INR 1.5-2.5)
Number of subjects: 148

Group type: COMPARATOR
Intervention: CONVENTIONAL-INR group (target INR 2.0-3.0)
Number of subjects: 148
Study: 27353466

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g, three times daily for 7 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 24245844

Group type: EXPERIMENTAL
Intervention: Intervention group with preformulated implementation intentions added to the information leaflet
Number of subjects: 23182

Group type: COMPARATOR
Intervention: Control group without implementation intentions
Number of subjects: 23182

Group type: EXPERIMENTAL
Intervention: Intervention in the lowest socioeconomic status (SES) tertile
Number of subjects: 23182

Group type: COMPARATOR
Intervention: Control in the lowest SES tertile
Number of subjects: 23182

Group type: EXPERIMENTAL
Intervention: Intervention in the least deprived tertile
Number of subjects: 23182

Group type: COMPARATOR
Intervention: Control in the least deprived tertile
Number of subjects: 23182

Group type: EXPERIMENTAL
Intervention: Intervention in the middle SES tertile
Number of subjects: 23182

Group type: COMPARATOR
Intervention: Control in the middle SES tertile
Number of subjects: 23182
Study: 22019438

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Apple+Spinach
Number of subjects: 30
Study: 19875483

Group type: EXPERIMENTAL
Intervention: 30-min meal
Number of subjects: 17

Group type: COMPARATOR
Intervention: 5-min meal
Number of subjects: 17
Study: 17970818

Group type: EXPERIMENTAL
Intervention: proposed treatment method
Number of subjects: 0

Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study: 16436240

Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive community treatment with family involvement and social skills training)
Number of subjects: 547